Panitumumab (Vectibix)

Panitumumab at a glance

Panitumumab, also called Vectibix, is a monoclonal antibody: a laboratory-made protein designed to recognise a particular target. It blocks the epidermal growth factor receptor, or EGFR. Although it is an antibody, it is not an immune-checkpoint inhibitor. It may be prescribed alone or with other cancer medicines.

The usual dose is calculated from body weight and given every two weeks. Treatment continues while its benefit remains worthwhile and side effects are acceptable. A pause or dose change may be needed to protect your health; it does not automatically mean the treatment has failed.

Skin and nail effects are very common. Magnesium and other minerals in the blood may fall, sometimes without obvious symptoms. Monitoring continues after the last infusion. Most side effects can be managed, but severe skin infection, lung inflammation, allergic reactions and damage to the surface of the eye require prompt specialist care.

What panitumumab is and how it works

EGFR sits on the surface of some cells. When activated, it passes messages into the cell that support growth and division. Panitumumab attaches to EGFR and interferes with those messages. This may help slow cancer growth in a suitable treatment setting. It does not guarantee that treatment will work for an individual.

EGFR also has normal jobs in healthy skin and other tissues. Blocking it can therefore cause an acne-like rash, dry or cracked skin, inflammation around the nails and eye symptoms. These effects do not mean your skin is dirty or that you have ordinary teenage acne. They need care designed for this treatment.

Genes called KRAS and NRAS make proteins further along the growth-signalling pathway. Certain changes, called mutations, can keep that pathway active despite EGFR blockade. This is why the exact molecular test result and the accompanying medicine matter.

How the team decides whether it is suitable

Your oncologist considers the diagnosis, previous treatment, molecular results, general fitness, other illnesses and the applicable prescribing information. In usual single-agent and relevant chemotherapy plans, testing must show wild-type RAS: no relevant mutation in either KRAS or NRAS. An unknown result is not the same as a normal result. Using an unsuitable anti-EGFR plan can expose someone to harm without benefit.

There is an important specific exception in current US information. Panitumumab may be paired with sotorasib when testing confirms the particular KRAS G12C mutation. Sotorasib targets that altered protein, while panitumumab blocks EGFR. This does not make panitumumab alone appropriate for any RAS-mutated tumour. The reviewed European Vectibix information and some patient websites retain a wild-type RAS framework, so a statement that panitumumab can never be used with a RAS mutation is too broad.

Tell the oncologist about previous serious allergic reactions, lung inflammation or lung scarring, severe dry eyes, previous corneal problems and significant skin disease. European information lists existing interstitial pneumonitis or pulmonary fibrosis as contraindications; US information requires careful assessment of benefit and risk. Kidney or liver impairment and frailty need individual assessment. Safety and effectiveness in children have not been established.

Before treatment starts

The team checks your molecular test report and reviews all planned cancer medicines. Blood tests include magnesium, calcium and other electrolytes, such as potassium. Electrolytes are minerals that help nerves, muscles and the heart function normally. Kidney and liver tests and blood counts help assess the complete treatment plan.

Your skin, nails, mouth and any existing eye symptoms should be discussed before the first infusion. Tell the team if you wear contact lenses: these can increase the risk of inflammation or ulceration of the cornea, the clear front surface of the eye. A skin-care plan started early is usually easier to follow than waiting until the rash becomes painful.

Bring a list of prescription medicines, supplements, herbal products and anything bought without a prescription. Mention diuretics, medicines for heartburn, previous mineral deficiencies, persistent diarrhoea and any fluid restriction. These details help the team interpret electrolyte results and choose safe supportive treatment. Do not stop medicines yourself.

Discuss pregnancy possibility, contraception and fertility before starting. Your team may arrange a pregnancy test according to your circumstances and local practice. Obtain the hospital's urgent advice details, its temperature instructions, and a clear plan for diarrhoea or a rapidly worsening rash.

How treatment is given

The infusion appointment

Panitumumab is given intravenously, meaning into a vein, in a healthcare setting with staff and equipment to manage a serious reaction. It may run through a small cannula in the arm or an existing central line or port. It is not a tablet, a home injection or an injection under the skin in the reviewed product information.

The usual dose is 6 mg per kilogram of body weight every 14 days. Your pharmacist prepares the diluted medicine and the nurse gives it using an infusion pump and a special low-protein-binding filter. The line is flushed before and after treatment to avoid mixing it with other medicines. It must not be given as a rapid intravenous push.

For doses of 1,000 mg or less, the first infusion usually takes about 60 minutes. If tolerated, later infusions may take 30–60 minutes. Doses above 1,000 mg are infused over about 90 minutes. Checks, preparation, accompanying medicines and observation make the whole appointment longer than the drip itself.

Premedicines, reactions and line care

Your team decides whether you need medicines before the infusion or extra fluids. The US label does not establish that routine premedication prevents panitumumab infusion reactions, and there is no universal fixed premedication package for every patient. Medicines required for a chemotherapy partner still need to be taken as prescribed.

Tell the nurse immediately about flushing, chills, itching, chest or back discomfort, dizziness, wheezing or swelling. The nurse may slow or stop the infusion and treat the reaction. Severe reactions require the infusion to stop. European information requires permanent discontinuation for severe or life-threatening reactions; US decisions also consider severity and persistence. Symptoms can also develop after you leave, including more than 24 hours later; new breathing difficulty or throat swelling is an emergency.

Report burning, pain, redness, swelling or leakage around the line promptly. Follow your unit's instructions for keeping a central-line dressing clean and dry. Do not adjust the pump or try to clear a blocked line yourself.

Delays and accompanying sotorasib

If you cannot attend, contact the unit to rearrange safely. A delayed infusion is not replaced with an extra dose. Vomiting cannot remove a medicine already given into a vein, but persistent vomiting still needs assessment for dehydration. Any oral partner has its own missed-dose and vomiting instructions.

When used with sotorasib under the US plan, the first sotorasib dose is taken before the first panitumumab infusion. If sotorasib is withheld, panitumumab is also withheld; if sotorasib is permanently stopped, panitumumab is also stopped in that combination. Tell the infusion team about any interruption of your tablets before attending. The reverse is not automatic: the specialist may sometimes continue sotorasib if panitumumab stops.

Monitoring and checking whether treatment is working

Magnesium and calcium are checked before treatment, periodically during it and for up to eight weeks after completion. Potassium and other relevant electrolytes also need monitoring and replacement when necessary. The labels do not prescribe one universal weekly schedule; frequency depends on results, symptoms and the other medicines you receive.

You may need prescribed supplements by mouth or through a drip. Do not choose the dose yourself, because kidney function and the balance between different minerals matter. Some oral magnesium preparations can worsen diarrhoea; tell the team rather than simply abandoning replacement.

At visits, report rash severity, painful nail folds, mouth sores, bowel changes, eye symptoms and any new cough or breathlessness. Severe or repeated skin toxicity may require a delay, reduction or permanent stopping, with the team deciding when recovery is sufficient.

Scans, examination, symptoms and sometimes tumour markers help assess benefit. Rash severity is not a reliable personal test of whether your cancer is responding. Neither absence of rash nor a treatment pause proves failure.

Sotorasib adds liver and lung precautions. Its US information specifies liver tests before treatment, every three weeks for the first three months, then monthly or as clinically indicated. Report yellow eyes or skin, dark urine or new breathing symptoms promptly. This extra schedule belongs to the combination plan.

Common side effects and practical management

Acne-like rash and dry skin

A rash often begins during the first few weeks, commonly on the face, scalp, upper chest or back. Skin may itch, flake, feel tender or develop small inflamed spots. Tell the team early, even if the area seems small, because early management can prevent painful cracks and infection.

Use a gentle, fragrance-free moisturiser and mild cleansing products recommended by the team. Avoid scrubbing, squeezing spots and starting ordinary acne treatments without advice; products that dry or irritate the skin can make this rash harder to manage. Ask before using steroid creams, particularly near the eyes.

Your clinician may prescribe a mild topical steroid and an oral antibiotic such as doxycycline as part of a prevention or treatment plan. An antibiotic used to help control this rash does not necessarily mean you have a bacterial infection. Follow the prescribed duration and application instructions rather than copying another patient's doses.

Sun sensitivity

Sunlight can make the rash worse. Use broad-spectrum sunscreen, protective clothing and a hat, and seek shade. Macmillan recommends at least SPF 30. Avoid deliberate tanning. US product information advises limiting sun exposure during treatment and for two months after the final dose; continue protection longer if your skin remains sensitive or your team advises it.

Nail and hair changes

The skin beside fingernails or toenails can become swollen, sore or infected, called paronychia. Keep nails clean and reasonably short, avoid cutting cuticles, and protect hands during wet work. Comfortable footwear reduces rubbing. Report increasing pain, pus, spreading redness or difficulty walking or using your hands.

Hair may gradually thin or change texture, while facial hair or eyelashes may grow more. Complete scalp hair loss is less typical with panitumumab alone, but chemotherapy partners can change that risk. Long eyelashes may rub the eye; ask for professional advice and do not trim them yourself.

Diarrhoea, nausea and reduced appetite

Follow the anti-diarrhoea plan supplied by the team and drink regularly unless you have a prescribed fluid restriction. Report a clear increase in stool frequency, persistent loose stools, dizziness or reduced urine. If you have a stoma, a substantial increase in output also matters. Severe diarrhoea can cause dehydration and kidney injury, so do not wait until your next infusion.

Anti-sickness medicines, smaller meals and regular sips may help nausea. Ask for dietetic support if appetite loss or mouth symptoms affect your weight. Persistent vomiting or inability to drink needs prompt advice. Severe abdominal pain, blood in stools or a swollen abdomen needs urgent assessment.

Mouth soreness and tiredness

Use a soft toothbrush and the mouth-care routine recommended by the unit. Softer foods may be easier with ulcers or a sore mouth. Report pain that prevents eating or drinking, and check before using a mouthwash or topical treatment.

Fatigue can reflect treatment, poor sleep, dehydration, anaemia or the cancer itself. Balance rest with gentle activity when possible. New marked weakness, palpitations or breathlessness should be assessed rather than assumed to be ordinary tiredness.

Less common but important side effects

Severe skin reactions and infection

Skin damage can become infected. Rapidly spreading redness, warmth, swelling, discharge, fever or severe pain needs urgent medical assessment. Serious infections of deeper tissues and sepsis, a dangerous whole-body response to infection, have occurred. Pain that seems disproportionate to the visible skin change is particularly concerning.

Rarely, blistering, peeling or painful sores involving skin, mouth, eyes or genitals can signal a severe skin reaction such as Stevens–Johnson syndrome or toxic epidermal necrolysis. Seek immediate hospital assessment. The team will withhold or stop panitumumab when severe complications occur; do not treat this as an ordinary rash to watch at home.

Low magnesium, calcium or potassium

These levels can fall progressively. You may notice muscle cramps, twitching, tingling, unusual weakness or palpitations, but blood tests may find a problem before symptoms appear. A seizure, collapse or severe heart symptoms is an emergency. Replacement and repeat tests may remain necessary after infusions stop.

Eye inflammation and corneal injury

Watery or dry eyes can occur, but new pain, redness, sensitivity to light or blurred vision requires prompt contact with the team and often urgent eye-specialist assessment. Keratitis means inflammation of the cornea; ulcerative keratitis involves a sore on that surface and can rarely progress to a hole, called perforation. Treatment may need interruption or stopping.

Remove contact lenses if the eye becomes painful or inflamed and seek advice before wearing them again. Do not assume redness is simple conjunctivitis or treat it with leftover antibiotic or steroid drops. Sudden loss of vision or severe eye pain needs emergency care.

Lung inflammation

Panitumumab can cause interstitial lung disease, an inflammation of lung tissue that can be serious or fatal. New or worsening cough, breathlessness or fever needs urgent assessment. Infection and other conditions can look similar, so symptoms cannot be diagnosed at home. The team interrupts panitumumab while investigating new or worsening lung symptoms; confirmed interstitial lung disease requires permanent discontinuation.

Blood clots and other treatment effects

Blood clots have been reported in the populations studied, and cancer and accompanying treatment also affect risk. Contact the team urgently for a new painful, swollen leg. Sudden chest pain, unexplained severe breathlessness or coughing blood needs emergency care. Blood-count changes and infection risk vary with the complete regimen; follow your hospital's fever instructions even if you are receiving a targeted medicine.

Other medicines, supplements and vaccinations

An infusion can still interact with a treatment plan. Ask the oncology pharmacist to check new medicines, supplements and herbal products. Panitumumab itself does not have a tablet-style fasting rule or an acid-suppressant spacing rule, but a partner medicine may.

Some anticancer combinations are unsafe. Panitumumab should not be added to bevacizumab with chemotherapy because studies found increased toxicity and deaths. European information also advises against the chemotherapy schedule called IFL; this is different from FOLFIRI. Your oncologist selects and checks the whole regimen rather than combining individually familiar medicines.

Sotorasib has important interactions, including with proton-pump inhibitors, H2 blockers and certain other medicines. If this is your partner treatment, ask for its separate written instructions before changing heartburn treatment. These restrictions should not be incorrectly applied to panitumumab alone.

Discuss vaccinations with the team. Suitability and timing, especially for live vaccines, depend on immune function and all accompanying treatment. Panitumumab does not automatically require the same infection-prevention medicines as every other antibody drug.

Everyday life during treatment

Work and usual activities may continue with adjustments for appointments, fatigue or sore skin. Plan practical help if your hands or feet become painful. Gentle activity and regular meals can support recovery, while troublesome symptoms deserve treatment rather than being accepted as unavoidable.

Panitumumab itself does not require fasting before an infusion. Check whether another medicine or test changes your instructions. Follow any prescribed fluid restriction when managing diarrhoea or hot weather. The healthcare facility stores and prepares the vials; you should not refrigerate, mix or transport them yourself unless the pharmacy has specifically organised this.

Avoid driving or machinery when dizziness, fatigue, visual symptoms or reduced concentration affect safety. Arrange transport for an early visit if you do not know how you will feel. Plan travel around infusions, blood tests and access to urgent care, and maintain sun protection.

Tell your dentist and other clinicians about all cancer treatment before procedures. Ask for support with changes in appearance, sleep, relationships or sexual comfort. A visible rash can be distressing even when medically graded as mild; its effect on your daily life matters when planning care.

Fertility, contraception, pregnancy and breastfeeding

Panitumumab may harm an unborn baby and increase the risk of pregnancy loss. Patients who could become pregnant need effective contraception during treatment and for at least two months after the last dose. Tell the team immediately if pregnancy occurs or is suspected. A partner medicine may require longer precautions.

Do not breastfeed during treatment or for two months after the final dose. Animal findings suggest that panitumumab may reduce female fertility; the effects in those studies were reversible, but this does not predict an individual's recovery. Discuss fertility preservation before treatment when relevant.

The reviewed panitumumab labels do not set a fixed male contraception interval. Ask the team for the advice applying to your complete regimen, including precautions for partners and sex during chemotherapy. Never shorten a partner medicine's longer contraception interval by relying only on the panitumumab interval.

After treatment finishes

Keep the planned blood-test appointments for up to eight weeks after the last infusion, particularly for magnesium, calcium and potassium. Continue replacement medicines until the team changes the prescription. Ongoing cramps, weakness, palpitations, diarrhoea or reduced urine should be reported even though treatment has ended.

Skin, nail and hair changes often improve gradually rather than immediately. Continue gentle skin care and follow-up for any infected or painful areas. Limit sun exposure for two months after the final dose as advised in US information, and longer if your skin remains sensitive. Eye or breathing symptoms still need prompt assessment.

Continue contraception and breastfeeding precautions for their full intervals. Your team will explain future scans, symptom monitoring and whether other cancer medicines continue. Do not restart an interrupted partner medicine simply because the infusion course has finished.

Frequently asked questions